調査レポート | • レポートコード：QYR2104Z1837 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、糖尿病性末梢神経障害治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アンチムノセル、ASP-8477、BNV-222、カプサイシン、CBX-129801、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・糖尿病性末梢神経障害治療の市場動向 ・企業の競争状況、市場シェア ・糖尿病性末梢神経障害治療の種類別市場規模（アンチムノセル、ASP-8477、BNV-222、カプサイシン、CBX-129801、その他） ・糖尿病性末梢神経障害治療の用途別市場規模（病院、クリニック、その他） ・糖尿病性末梢神経障害治療の北米市場規模2016-2027（アメリカ、カナダ） ・糖尿病性末梢神経障害治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・糖尿病性末梢神経障害治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・糖尿病性末梢神経障害治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・糖尿病性末梢神経障害治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Achelios Therapeutics Inc、Celgene Corp、Commence Bio Inc、Grunenthal GmbH、Immune Pharmaceuticals Inc、KPI Therapeutics Inc、Medifron DBT Co Ltd、Mitsubishi Tanabe Pharma Corp、Novaremed Ltd、Reata Pharmaceuticals Inc、Relief Therapeutics Holding AG、ViroMed Co Ltd） ・結論 |
Market Analysis and Insights: Global Diabetic Peripheral Neuropathy Treatment Market
The global Diabetic Peripheral Neuropathy Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Diabetic Peripheral Neuropathy Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Diabetic Peripheral Neuropathy Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Diabetic Peripheral Neuropathy Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Diabetic Peripheral Neuropathy Treatment market.
Global Diabetic Peripheral Neuropathy Treatment Scope and Market Size
Diabetic Peripheral Neuropathy Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Diabetic Peripheral Neuropathy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Antimunocel
ASP-8477
BNV-222
Capsaicin
CBX-129801
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Achelios Therapeutics Inc
Celgene Corp
Commence Bio Inc
Grunenthal GmbH
Immune Pharmaceuticals Inc
KPI Therapeutics Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Novaremed Ltd
Grunenthal GmbH
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diabetic Peripheral Neuropathy Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Antimunocel
1.2.3 ASP-8477
1.2.4 BNV-222
1.2.5 Capsaicin
1.2.6 CBX-129801
1.2.7 Others
1.3 Market by Application
1.3.1 Global Diabetic Peripheral Neuropathy Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Peripheral Neuropathy Treatment Market Perspective (2016-2027)
2.2 Diabetic Peripheral Neuropathy Treatment Growth Trends by Regions
2.2.1 Diabetic Peripheral Neuropathy Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Diabetic Peripheral Neuropathy Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Diabetic Peripheral Neuropathy Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Diabetic Peripheral Neuropathy Treatment Industry Dynamic
2.3.1 Diabetic Peripheral Neuropathy Treatment Market Trends
2.3.2 Diabetic Peripheral Neuropathy Treatment Market Drivers
2.3.3 Diabetic Peripheral Neuropathy Treatment Market Challenges
2.3.4 Diabetic Peripheral Neuropathy Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Peripheral Neuropathy Treatment Players by Revenue
3.1.1 Global Top Diabetic Peripheral Neuropathy Treatment Players by Revenue (2016-2021)
3.1.2 Global Diabetic Peripheral Neuropathy Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Diabetic Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Diabetic Peripheral Neuropathy Treatment Revenue
3.4 Global Diabetic Peripheral Neuropathy Treatment Market Concentration Ratio
3.4.1 Global Diabetic Peripheral Neuropathy Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Peripheral Neuropathy Treatment Revenue in 2020
3.5 Diabetic Peripheral Neuropathy Treatment Key Players Head office and Area Served
3.6 Key Players Diabetic Peripheral Neuropathy Treatment Product Solution and Service
3.7 Date of Enter into Diabetic Peripheral Neuropathy Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Diabetic Peripheral Neuropathy Treatment Breakdown Data by Type
4.1 Global Diabetic Peripheral Neuropathy Treatment Historic Market Size by Type (2016-2021)
4.2 Global Diabetic Peripheral Neuropathy Treatment Forecasted Market Size by Type (2022-2027)
5 Diabetic Peripheral Neuropathy Treatment Breakdown Data by Application
5.1 Global Diabetic Peripheral Neuropathy Treatment Historic Market Size by Application (2016-2021)
5.2 Global Diabetic Peripheral Neuropathy Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Diabetic Peripheral Neuropathy Treatment Market Size (2016-2027)
6.2 North America Diabetic Peripheral Neuropathy Treatment Market Size by Type
6.2.1 North America Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2021)
6.2.2 North America Diabetic Peripheral Neuropathy Treatment Market Size by Type (2022-2027)
6.2.3 North America Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2027)
6.3 North America Diabetic Peripheral Neuropathy Treatment Market Size by Application
6.3.1 North America Diabetic Peripheral Neuropathy Treatment Market Size by Application (2016-2021)
6.3.2 North America Diabetic Peripheral Neuropathy Treatment Market Size by Application (2022-2027)
6.3.3 North America Diabetic Peripheral Neuropathy Treatment Market Size by Application (2016-2027)
6.4 North America Diabetic Peripheral Neuropathy Treatment Market Size by Country
6.4.1 North America Diabetic Peripheral Neuropathy Treatment Market Size by Country (2016-2021)
6.4.2 North America Diabetic Peripheral Neuropathy Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Diabetic Peripheral Neuropathy Treatment Market Size (2016-2027)
7.2 Europe Diabetic Peripheral Neuropathy Treatment Market Size by Type
7.2.1 Europe Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2021)
7.2.2 Europe Diabetic Peripheral Neuropathy Treatment Market Size by Type (2022-2027)
7.2.3 Europe Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2027)
7.3 Europe Diabetic Peripheral Neuropathy Treatment Market Size by Application
7.3.1 Europe Diabetic Peripheral Neuropathy Treatment Market Size by Application (2016-2021)
7.3.2 Europe Diabetic Peripheral Neuropathy Treatment Market Size by Application (2022-2027)
7.3.3 Europe Diabetic Peripheral Neuropathy Treatment Market Size by Application (2016-2027)
7.4 Europe Diabetic Peripheral Neuropathy Treatment Market Size by Country
7.4.1 Europe Diabetic Peripheral Neuropathy Treatment Market Size by Country (2016-2021)
7.4.2 Europe Diabetic Peripheral Neuropathy Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size (2016-2027)
8.2 Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Type
8.2.1 Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Application
8.3.1 Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Region
8.4.1 Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Diabetic Peripheral Neuropathy Treatment Market Size (2016-2027)
9.2 Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Type
9.2.1 Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2027)
9.3 Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Application
9.3.1 Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Application (2016-2027)
9.4 Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Country
9.4.1 Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size (2016-2027)
10.2 Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Type
10.2.1 Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Application
10.3.1 Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Country
10.4.1 Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Achelios Therapeutics Inc
11.1.1 Achelios Therapeutics Inc Company Details
11.1.2 Achelios Therapeutics Inc Business Overview
11.1.3 Achelios Therapeutics Inc Diabetic Peripheral Neuropathy Treatment Introduction
11.1.4 Achelios Therapeutics Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
11.1.5 Achelios Therapeutics Inc Recent Development
11.2 Celgene Corp
11.2.1 Celgene Corp Company Details
11.2.2 Celgene Corp Business Overview
11.2.3 Celgene Corp Diabetic Peripheral Neuropathy Treatment Introduction
11.2.4 Celgene Corp Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
11.2.5 Celgene Corp Recent Development
11.3 Commence Bio Inc
11.3.1 Commence Bio Inc Company Details
11.3.2 Commence Bio Inc Business Overview
11.3.3 Commence Bio Inc Diabetic Peripheral Neuropathy Treatment Introduction
11.3.4 Commence Bio Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
11.3.5 Commence Bio Inc Recent Development
11.4 Grunenthal GmbH
11.4.1 Grunenthal GmbH Company Details
11.4.2 Grunenthal GmbH Business Overview
11.4.3 Grunenthal GmbH Diabetic Peripheral Neuropathy Treatment Introduction
11.4.4 Grunenthal GmbH Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
11.4.5 Grunenthal GmbH Recent Development
11.5 Immune Pharmaceuticals Inc
11.5.1 Immune Pharmaceuticals Inc Company Details
11.5.2 Immune Pharmaceuticals Inc Business Overview
11.5.3 Immune Pharmaceuticals Inc Diabetic Peripheral Neuropathy Treatment Introduction
11.5.4 Immune Pharmaceuticals Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
11.5.5 Immune Pharmaceuticals Inc Recent Development
11.6 KPI Therapeutics Inc
11.6.1 KPI Therapeutics Inc Company Details
11.6.2 KPI Therapeutics Inc Business Overview
11.6.3 KPI Therapeutics Inc Diabetic Peripheral Neuropathy Treatment Introduction
11.6.4 KPI Therapeutics Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
11.6.5 KPI Therapeutics Inc Recent Development
11.7 Medifron DBT Co Ltd
11.7.1 Medifron DBT Co Ltd Company Details
11.7.2 Medifron DBT Co Ltd Business Overview
11.7.3 Medifron DBT Co Ltd Diabetic Peripheral Neuropathy Treatment Introduction
11.7.4 Medifron DBT Co Ltd Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
11.7.5 Medifron DBT Co Ltd Recent Development
11.8 Mitsubishi Tanabe Pharma Corp
11.8.1 Mitsubishi Tanabe Pharma Corp Company Details
11.8.2 Mitsubishi Tanabe Pharma Corp Business Overview
11.8.3 Mitsubishi Tanabe Pharma Corp Diabetic Peripheral Neuropathy Treatment Introduction
11.8.4 Mitsubishi Tanabe Pharma Corp Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
11.8.5 Mitsubishi Tanabe Pharma Corp Recent Development
11.9 Novaremed Ltd
11.9.1 Novaremed Ltd Company Details
11.9.2 Novaremed Ltd Business Overview
11.9.3 Novaremed Ltd Diabetic Peripheral Neuropathy Treatment Introduction
11.9.4 Novaremed Ltd Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
11.9.5 Novaremed Ltd Recent Development
11.10 Reata Pharmaceuticals Inc
11.10.1 Reata Pharmaceuticals Inc Company Details
11.10.2 Reata Pharmaceuticals Inc Business Overview
11.10.3 Reata Pharmaceuticals Inc Diabetic Peripheral Neuropathy Treatment Introduction
11.10.4 Reata Pharmaceuticals Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
11.10.5 Reata Pharmaceuticals Inc Recent Development
11.11 Relief Therapeutics Holding AG
11.11.1 Relief Therapeutics Holding AG Company Details
11.11.2 Relief Therapeutics Holding AG Business Overview
11.11.3 Relief Therapeutics Holding AG Diabetic Peripheral Neuropathy Treatment Introduction
11.11.4 Relief Therapeutics Holding AG Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
11.11.5 Relief Therapeutics Holding AG Recent Development
11.12 ViroMed Co Ltd
11.12.1 ViroMed Co Ltd Company Details
11.12.2 ViroMed Co Ltd Business Overview
11.12.3 ViroMed Co Ltd Diabetic Peripheral Neuropathy Treatment Introduction
11.12.4 ViroMed Co Ltd Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
11.12.5 ViroMed Co Ltd Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Diabetic Peripheral Neuropathy Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Antimunocel
Table 3. Key Players of ASP-8477
Table 4. Key Players of BNV-222
Table 5. Key Players of Capsaicin
Table 6. Key Players of CBX-129801
Table 7. Key Players of Others
Table 8. Global Diabetic Peripheral Neuropathy Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Diabetic Peripheral Neuropathy Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Diabetic Peripheral Neuropathy Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Diabetic Peripheral Neuropathy Treatment Market Share by Regions (2016-2021)
Table 12. Global Diabetic Peripheral Neuropathy Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Diabetic Peripheral Neuropathy Treatment Market Share by Regions (2022-2027)
Table 14. Diabetic Peripheral Neuropathy Treatment Market Trends
Table 15. Diabetic Peripheral Neuropathy Treatment Market Drivers
Table 16. Diabetic Peripheral Neuropathy Treatment Market Challenges
Table 17. Diabetic Peripheral Neuropathy Treatment Market Restraints
Table 18. Global Diabetic Peripheral Neuropathy Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Diabetic Peripheral Neuropathy Treatment Market Share by Players (2016-2021)
Table 20. Global Top Diabetic Peripheral Neuropathy Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Peripheral Neuropathy Treatment as of 2020)
Table 21. Ranking of Global Top Diabetic Peripheral Neuropathy Treatment Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Diabetic Peripheral Neuropathy Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Diabetic Peripheral Neuropathy Treatment Product Solution and Service
Table 25. Date of Enter into Diabetic Peripheral Neuropathy Treatment Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Diabetic Peripheral Neuropathy Treatment Revenue Market Share by Type (2016-2021)
Table 29. Global Diabetic Peripheral Neuropathy Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Diabetic Peripheral Neuropathy Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Diabetic Peripheral Neuropathy Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Diabetic Peripheral Neuropathy Treatment Revenue Market Share by Application (2016-2021)
Table 33. Global Diabetic Peripheral Neuropathy Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Diabetic Peripheral Neuropathy Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Diabetic Peripheral Neuropathy Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Diabetic Peripheral Neuropathy Treatment Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Diabetic Peripheral Neuropathy Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Diabetic Peripheral Neuropathy Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Diabetic Peripheral Neuropathy Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Diabetic Peripheral Neuropathy Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Diabetic Peripheral Neuropathy Treatment Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Diabetic Peripheral Neuropathy Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Diabetic Peripheral Neuropathy Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Diabetic Peripheral Neuropathy Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Diabetic Peripheral Neuropathy Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 65. Achelios Therapeutics Inc Company Details
Table 66. Achelios Therapeutics Inc Business Overview
Table 67. Achelios Therapeutics Inc Diabetic Peripheral Neuropathy Treatment Product
Table 68. Achelios Therapeutics Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 69. Achelios Therapeutics Inc Recent Development
Table 70. Celgene Corp Company Details
Table 71. Celgene Corp Business Overview
Table 72. Celgene Corp Diabetic Peripheral Neuropathy Treatment Product
Table 73. Celgene Corp Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 74. Celgene Corp Recent Development
Table 75. Commence Bio Inc Company Details
Table 76. Commence Bio Inc Business Overview
Table 77. Commence Bio Inc Diabetic Peripheral Neuropathy Treatment Product
Table 78. Commence Bio Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 79. Commence Bio Inc Recent Development
Table 80. Grunenthal GmbH Company Details
Table 81. Grunenthal GmbH Business Overview
Table 82. Grunenthal GmbH Diabetic Peripheral Neuropathy Treatment Product
Table 83. Grunenthal GmbH Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 84. Grunenthal GmbH Recent Development
Table 85. Immune Pharmaceuticals Inc Company Details
Table 86. Immune Pharmaceuticals Inc Business Overview
Table 87. Immune Pharmaceuticals Inc Diabetic Peripheral Neuropathy Treatment Product
Table 88. Immune Pharmaceuticals Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 89. Immune Pharmaceuticals Inc Recent Development
Table 90. KPI Therapeutics Inc Company Details
Table 91. KPI Therapeutics Inc Business Overview
Table 92. KPI Therapeutics Inc Diabetic Peripheral Neuropathy Treatment Product
Table 93. KPI Therapeutics Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 94. KPI Therapeutics Inc Recent Development
Table 95. Medifron DBT Co Ltd Company Details
Table 96. Medifron DBT Co Ltd Business Overview
Table 97. Medifron DBT Co Ltd Diabetic Peripheral Neuropathy Treatment Product
Table 98. Medifron DBT Co Ltd Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 99. Medifron DBT Co Ltd Recent Development
Table 100. Mitsubishi Tanabe Pharma Corp Company Details
Table 101. Mitsubishi Tanabe Pharma Corp Business Overview
Table 102. Mitsubishi Tanabe Pharma Corp Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 103. Mitsubishi Tanabe Pharma Corp Recent Development
Table 104. Novaremed Ltd Company Details
Table 105. Novaremed Ltd Business Overview
Table 106. Novaremed Ltd Diabetic Peripheral Neuropathy Treatment Product
Table 107. Novaremed Ltd Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 108. Novaremed Ltd Recent Development
Table 109. Reata Pharmaceuticals Inc Company Details
Table 110. Reata Pharmaceuticals Inc Business Overview
Table 111. Reata Pharmaceuticals Inc Diabetic Peripheral Neuropathy Treatment Product
Table 112. Reata Pharmaceuticals Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 113. Reata Pharmaceuticals Inc Recent Development
Table 114. Relief Therapeutics Holding AG Company Details
Table 115. Relief Therapeutics Holding AG Business Overview
Table 116. Relief Therapeutics Holding AG Diabetic Peripheral Neuropathy Treatment Product
Table 117. Relief Therapeutics Holding AG Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 118. Relief Therapeutics Holding AG Recent Development
Table 119. ViroMed Co Ltd Company Details
Table 120. ViroMed Co Ltd Business Overview
Table 121. ViroMed Co Ltd Diabetic Peripheral Neuropathy Treatment Product
Table 122. ViroMed Co Ltd Revenue in Diabetic Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 123. ViroMed Co Ltd Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Diabetic Peripheral Neuropathy Treatment Market Share by Type: 2020 VS 2027
Figure 2. Antimunocel Features
Figure 3. ASP-8477 Features
Figure 4. BNV-222 Features
Figure 5. Capsaicin Features
Figure 6. CBX-129801 Features
Figure 7. Others Features
Figure 8. Global Diabetic Peripheral Neuropathy Treatment Market Share by Application: 2020 VS 2027
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Others Case Studies
Figure 12. Diabetic Peripheral Neuropathy Treatment Report Years Considered
Figure 13. Global Diabetic Peripheral Neuropathy Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Diabetic Peripheral Neuropathy Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Diabetic Peripheral Neuropathy Treatment Market Share by Regions: 2020 VS 2027
Figure 16. Global Diabetic Peripheral Neuropathy Treatment Market Share by Regions (2022-2027)
Figure 17. Global Diabetic Peripheral Neuropathy Treatment Market Share by Players in 2020
Figure 18. Global Top Diabetic Peripheral Neuropathy Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Peripheral Neuropathy Treatment as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Diabetic Peripheral Neuropathy Treatment Revenue in 2020
Figure 20. Global Diabetic Peripheral Neuropathy Treatment Revenue Market Share by Type (2016-2021)
Figure 21. Global Diabetic Peripheral Neuropathy Treatment Revenue Market Share by Type (2022-2027)
Figure 22. North America Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Diabetic Peripheral Neuropathy Treatment Market Share by Type (2016-2027)
Figure 24. North America Diabetic Peripheral Neuropathy Treatment Market Share by Application (2016-2027)
Figure 25. North America Diabetic Peripheral Neuropathy Treatment Market Share by Country (2016-2027)
Figure 26. United States Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Diabetic Peripheral Neuropathy Treatment Market Share by Type (2016-2027)
Figure 30. Europe Diabetic Peripheral Neuropathy Treatment Market Share by Application (2016-2027)
Figure 31. Europe Diabetic Peripheral Neuropathy Treatment Market Share by Country (2016-2027)
Figure 32. Germany Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Diabetic Peripheral Neuropathy Treatment Market Share by Region (2016-2027)
Figure 42. China Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Diabetic Peripheral Neuropathy Treatment Market Share by Type (2016-2027)
Figure 50. Latin America Diabetic Peripheral Neuropathy Treatment Market Share by Application (2016-2027)
Figure 51. Latin America Diabetic Peripheral Neuropathy Treatment Market Share by Country (2016-2027)
Figure 52. Mexico Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Share by Country (2016-2027)
Figure 58. Turkey Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Achelios Therapeutics Inc Revenue Growth Rate in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
Figure 62. Celgene Corp Revenue Growth Rate in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
Figure 63. Commence Bio Inc Revenue Growth Rate in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
Figure 64. Grunenthal GmbH Revenue Growth Rate in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
Figure 65. Immune Pharmaceuticals Inc Revenue Growth Rate in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
Figure 66. KPI Therapeutics Inc Revenue Growth Rate in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
Figure 67. Medifron DBT Co Ltd Revenue Growth Rate in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
Figure 68. Mitsubishi Tanabe Pharma Corp Revenue Growth Rate in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
Figure 69. Novaremed Ltd Revenue Growth Rate in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
Figure 70. Reata Pharmaceuticals Inc Revenue Growth Rate in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
Figure 71. Relief Therapeutics Holding AG Revenue Growth Rate in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
Figure 72. ViroMed Co Ltd Revenue Growth Rate in Diabetic Peripheral Neuropathy Treatment Business (2016-2021)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
世界の糖尿病性ニューロパチー治療（DN）市場規模・現状・予測（2021年-2027年） Diabetic neuropathy is a nerve damaging disorder associated with diabetes mellitus. Patients suffering from diabetes since a long time are prone to nerve damages throughout the body, as the symptoms of diabetic neuropathies cannot be diagnosed at an earlier stage. Although there is no cure for diabe…- 世界の糖尿病性ニューロパチー治療（DN）市場規模・現状・予測（2021年-2027年） Diabetic neuropathy is a nerve damaging disorder associated with diabetes mellitus. Patients suffering from diabetes since a long time are prone to nerve damages throughout the body, as the symptoms of diabetic neuropathies cannot be diagnosed at an earlier stage. Although there is no cure for diabe…
- 世界の末梢神経障害治療市場規模・現状・予測（2021年-2027年） Peripheral neuropathy is a set of symptoms caused by any damage to the nerves that are away from the brain and spinal cord. Peripheral neuropathy is not a single, homogenous disease, but it is a mix of different clinical presentations, natural histories, and pathology. Market Analysis and Insights: …
- 世界の末梢神経障害治療市場規模・現状・予測（2021年-2027年） Peripheral neuropathy is a set of symptoms caused by any damage to the nerves that are away from the brain and spinal cord. Peripheral neuropathy is not a single, homogenous disease, but it is a mix of different clinical presentations, natural histories, and pathology. Market Analysis and Insights: …
- 世界の化学療法誘発性末梢神経障害（CIPN）治療市場規模・現状・予測（2021年-2027年） CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemother…